The phase II GEMINI-HPB (NCT05775159) trial evaluated the efficacy and safety of volrustomig (anti-CTLA-4/anti-PD-1 bsAb) or rilvegostomig (anti-PD-1/anti-TIGIT bsAb) as monotherapy and/or in combination with anticancer agents in patients with HCC [Table 5]. Here, CTLA4 is linked to hepatocellular carcinoma.